Cancer drug directory
Educational information only. No dosage or personal treatment recommendations.
Osimertinib
Osimertinib is an oral targeted medicine for selected adults with non-small cell lung cancer (NSCLC) whose tumors carry specific activating EGFR mutations; its exact role depends on stage and prior treatment.
Pembrolizumab
Pembrolizumab removes PD-1-mediated inhibitory signaling from T cells, enabling antitumor immune responses in selected cancers, but it can also trigger inflammation in almost any normal organ.
Trastuzumab
Trastuzumab binds HER2 on tumors with high HER2 expression or gene amplification, blocks growth signaling, and recruits immune effector mechanisms; cardiac safety and accurate HER2 testing are central to its use.
Tamoxifen
Tamoxifen blocks estrogen-receptor signaling in breast tissue and is used to treat or reduce the risk of hormone-sensitive breast cancer, while exerting estrogen-like effects in some other tissues that explain both benefits and serious risks.